Plasma Total Antioxidant Activity in Comparison With Plasma NO and VEGF Levels in Patients With Metabolic Syndrome

被引:41
作者
Barylski, Marcin [2 ]
Kowalczyk, Edward [3 ]
Banach, Maciej [1 ]
Ciecwierz, Julita [3 ]
Pawlicki, Luejan [2 ]
Kowalski, Jan [2 ]
机构
[1] Med Univ Lodz, Dept Mol Cardionephrol & Hypertens, PL-90549 Lodz, Poland
[2] Med Univ Lodz, Dept Internal Dis & Cardiol Rehabil, PL-90549 Lodz, Poland
[3] Med Univ Lodz, Dept Pharmacol, PL-90549 Lodz, Poland
关键词
metabolic syndrome; plasma total antioxidant activity; nitric oxide; vascular endothelial growth factor; ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE-SYNTHASE; SUPEROXIDE ANION; GENERATION; ATHEROSCLEROSIS; ANGIOGENESIS; MECHANISMS; APOPTOSIS; THERAPY;
D O I
10.1177/0003319708327165
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Introduction: The aim of our study was to estimate plasma antioxidant activity as well as plasma nitric oxide (NO) and vascular endothelial growth factor levels in patients with metabolic syndrome compared with healthy participants. Material and Methods: Fifty patients (24 women and 26 men, mean age 55.9 +/- 11.8 years) with metabolic syndrome were compared with 25 healthy participants (12 women and 13 men, mean age 54.2 +/- 12.8 years). Plasma total antioxidant activity and plasma levels of NO and VEGF were determined in all participants. Results: In the patients with metabolic syndrome, plasma total antioxidant activity, nitric oxide, and vascular endothelial growth factor were significantly lower (P < .001) than that observed in healthy participants (3.2 +/- 1.6 vs 6.4 +/- 2.1 mM/L), (6.3 +/- 2.2 vs 9.8 +/- 2.7 mu M/L), and 71.0 +/- 16.9 vs 137.5 +/- 12.6 pg/mL), respectively. Conclusions: Decreased plasma total antioxidant activity, NO, and VEGF levels in patients with metabolic syndrome reflect significant endothelial dysfunction. This suggests that oxidation-reduction balance disorders might play an important role in this process
引用
收藏
页码:87 / 92
页数:6
相关论文
共 38 条
[1]  
Banach Maciej, 2004, Przegl Epidemiol, V58, P663
[2]  
Bartosz G., 1998, CURR TOP BIOPHYS SB, V22, P11
[3]  
Benzie IFF, 1999, METHOD ENZYMOL, V299, P15
[4]   Role of HIF-1α or in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis [J].
Carmeliet, P ;
Dor, Y ;
Herbert, JM ;
Fukumura, D ;
Brusselmans, K ;
Dewerchin, M ;
Neeman, M ;
Bono, F ;
Abramovitch, R ;
Maxwell, P ;
Koch, CJ ;
Ratcliffe, P ;
Moons, L ;
Jain, RK ;
Collen, D ;
Keshet, E .
NATURE, 1998, 394 (6692) :485-490
[5]   Prevention and treatment of the metabolic syndrome [J].
Daskalopoulou, SS ;
Mikhailidis, DP ;
Elisaf, A .
ANGIOLOGY, 2004, 55 (06) :589-612
[6]   VEGF - nitric oxide reciprocal regulation [J].
DembinskaKiec, A ;
Dulak, J ;
Partyka, L ;
Huk, I ;
Mailnski, T .
NATURE MEDICINE, 1997, 3 (11) :1177-1177
[7]  
Digiesi V, 2000, Clin Ter, V151, P15
[8]  
Doclani S, 2008, ARCH MED SCI, V4, P40
[9]   EFFECTS OF INFUSION OF L-ARGININE INTO THE LEFT ANTERIOR DESCENDING CORONARY-ARTERY ON ACETYLCHOLINE-INDUCED VASOCONSTRICTION OF HUMAN ATHEROMATOUS CORONARY-ARTERIES [J].
DUBOISRANDE, JL ;
ZELINSKY, R ;
ROUDOT, F ;
CHABRIER, PE ;
CASTAIGNE, A ;
GESCHWIND, H ;
ADNOT, S .
AMERICAN JOURNAL OF CARDIOLOGY, 1992, 70 (15) :1269-1275
[10]  
Dulak J, 2001, CIRCULATION, V104, pE48